TPIV 200

TapImmune Announces Phase 2 Ovarian Cancer Trial Study with AstraZeneca/MedImmune and Sloan Kettering Cancer Institute
Yahoo
Thu, 04/21/16 - 03:14 pm
TapImmune
AstraZenca
MedImmune
ovarian cancer
clinical trials
TPIV 200